{"title": "BioNTech - 17 Presseschau-Abs\u00e4tze - Seite 1 von 2 - Perlentaucher", "author": null, "url": "https://www.perlentaucher.de/stichwort/bio-ntech/presseschauen.html", "hostname": "perlentaucher.de", "description": null, "sitename": "Perlentaucher00", "date": "2023-10-26", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "\u2261\nStichwort\nBioNTech\n17 Presseschau-Abs\u00e4tze - Seite 1 von 2\n[9punkt](/9punkt/2021-05-07.html?highlight=BioNTech#a82515) [07.05.2021](/9punkt/2021-05-07.html?highlight=BioNTech#a82515) [ [\u2026] . 'Wir haben schon 200 Millionen Impfdosen exportiert', sagte eine Sprecherin. 'Damit haben wir genauso viel in die Welt geliefert wie an unsere eigenen B\u00fcrger.'\"\n\u00d6zlem T\u00fcreci, Miterfinderin des Biontech-Impfstoffs und Miteignerin der Firma spricht sich in diesem CNN-Interview nachvollziehbarerweise gegen eine Freigabe aus. Die Installation von Fabriken, die Beschaffung von Rohstoffen und die Weitergabe [\u2026] Weitergabe von Knowhow w\u00fcrden die Sache ohnehin nicht beschleunigen:\nEasing patent protection for vaccines is a bad idea, says Dr. Ozlem Tureci, co-founder and chief medical officer at BioNTech, which produces Pfizer's Covid-19 vaccine.\nIt \"will not increase the number of doses we will have available within the next\" year. https://t.co/Lx1uOd7FPr pic.twitter.com/oc39rA4W9Z- CNN (@CNN) May 6, 2021Es [\u2026] gibt eine Alternative zur Patentfreigabe, schreibt der Experte Axel Metzger im FAZ-Feuilleton, n\u00e4mlich Zwangslizenzen, die bereits jetzt bei \u00f6ffentlichem Notstand vergeben werden k\u00f6nnen. Firmen wie Biontech seien aber zur internationalen Kooperation bereit. Und es sei zu bedenken, \"dass eine Zwangslizenz allein noch niemanden in die Lage versetzt, technisch komplexe Impfstoffe sicher herzustellen. Wirksamer [\u2026] ](/9punkt/2021-05-07.html?highlight=BioNTech#a82515)", "language": null, "image": null, "pagetype": null, "links": ["/", "/mein", "http://www.twitter.com/perlentaucher00", "https://www.facebook.com/pages/Perlentaucher/148688561842109", "#", "/", "/teaserliste/1_Presseschauen.html", "/archive/fl/6.html", "/archive/fl/5.html", "/archive/fl/4.html", "/archive/fl/2.html", "/teaserliste/2_Buecher.html", "/teaserliste/5_Buecherschauen.html", "/vom-nachttisch-geraeumt/", "/tagtigall", "/wo-wir-nicht-sind/", "/fotolot/", "/vorworte/", "/vorgeblaettert/", "/sonstiges/stoebern.html", "/buchlink/", "/teaserliste/10_kino_tv.html", "/im-kino/", "/berlinale-blog/", "/teaserliste/3_Magazin.html", "/essay/", "/intervention/", "/meldungen/", "/dokumentation/", "/in-eigener-sache/", "/sitemap/", "/newsletter/", "https://eichendorff21.de", "/suche", "/werbung-mediadaten/werben-beim-perlentaucher.html", "/essay/perlentaucher-debatte-literaturkritik-im-netz.html", "/essay/aufruhr-im-zwischenreich-teil-1.html?highlight=", "/essay/monotheismus-debatte-im-perlentaucher.html", "/essay/beschneidungsdebatte.html", "/essay/islam-in-europa-chronologie-der-debatte.html", "/link-des-tages/der-karikaturenstreit-eine-europaeische-presseschau.html", "/link-des-tages/inhaltsverzeichnis-zur-walser-affaere-beim-perlentaucher.html", "/link-des-tages/links-und-hintergruende-zum-attentat-am-11-september.html", "/fallende-blaetter/uebersicht.html", "/ptautor/goetz-aly.html", "/ptautor/ilja-braun.html", "/ptautor/pascal-bruckner.html", "/ptautor/thierry-chervel.html", "/ptautor/thekla-dannenberg.html", "/ptautor/daniele-dellagli.html", "/ptautor/lukas-foerster.html", "/ptautor/thomas-groh.html", "/ptautor/andre-glucksmann.html", "/ptautor/juergen-habermas.html", "/ptautor/necla-kelek.html", "/ptautor/georg-klein.html", "/ptautor/ekkehard-knoerer.html", "/ptautor/marie-luise-knott.html", "/ptautor/wolfgang-kraushaar.html", "/ptautor/matthias-kuentzel.html", "/ptautor/eva-quistorp.html", "/ptautor/anja-seeliger.html", "/ptautor/wolfgang-ullrich.html", "/ptautor/martin-vogel.html", "/ptautor/arno-widmann.html", "/ptautor/ruediger-wischenbart.html", "/ptautoren/", "/stichwort/bio-ntech.html", "/stichwort/bio-ntech/buecher.html", "/9punkt/2021-12-31.html?highlight=BioNTech#a85728", "/9punkt/2021-12-31.html?highlight=BioNTech#a85728", "/9punkt/2021-12-31.html?highlight=BioNTech#a85728", "/9punkt/2021-12-17.html?highlight=BioNTech#a85551", "/9punkt/2021-12-17.html?highlight=BioNTech#a85551", "/9punkt/2021-12-17.html?highlight=BioNTech#a85551", "/9punkt/2021-11-22.html?highlight=BioNTech#a85190", "/9punkt/2021-11-22.html?highlight=BioNTech#a85190", "/9punkt/2021-11-22.html?highlight=BioNTech#a85190", "/9punkt/2021-08-09.html?highlight=BioNTech#a83769", "/9punkt/2021-08-09.html?highlight=BioNTech#a83769", "/9punkt/2021-08-09.html?highlight=BioNTech#a83769", "/9punkt/2021-05-07.html?highlight=BioNTech#a82515", "/9punkt/2021-05-07.html?highlight=BioNTech#a82515", "/9punkt/2021-05-07.html?highlight=BioNTech#a82515", "/9punkt/2021-05-05.html?highlight=BioNTech#a82486", "/9punkt/2021-05-05.html?highlight=BioNTech#a82486", "/9punkt/2021-05-05.html?highlight=BioNTech#a82486", "/9punkt/2021-04-14.html?highlight=BioNTech#a82208", "/9punkt/2021-04-14.html?highlight=BioNTech#a82208", "/9punkt/2021-04-14.html?highlight=BioNTech#a82208", "/magazinrundschau/2021-03-09.html?highlight=BioNTech#a81719", "/magazinrundschau/2021-03-09.html?highlight=BioNTech#a81719", "/magazinrundschau/2021-03-09.html?highlight=BioNTech#a81719", "/9punkt/2021-02-11.html?highlight=BioNTech#a81377", "/9punkt/2021-02-11.html?highlight=BioNTech#a81377", "/9punkt/2021-02-11.html?highlight=BioNTech#a81377", "/9punkt/2021-02-05.html?highlight=BioNTech#a81299", "/9punkt/2021-02-05.html?highlight=BioNTech#a81299", "/9punkt/2021-02-05.html?highlight=BioNTech#a81299", "/9punkt/2021-02-02.html?highlight=BioNTech#a81250", "/9punkt/2021-02-02.html?highlight=BioNTech#a81250", "/9punkt/2021-02-02.html?highlight=BioNTech#a81250", "/9punkt/2021-02-01.html?highlight=BioNTech#a81222", "/9punkt/2021-02-01.html?highlight=BioNTech#a81222", "/9punkt/2021-02-01.html?highlight=BioNTech#a81222", "/9punkt/2021-01-15.html?highlight=BioNTech#a81000", "/9punkt/2021-01-15.html?highlight=BioNTech#a81000", "/9punkt/2021-01-15.html?highlight=BioNTech#a81000", "/9punkt/2021-01-07.html?highlight=BioNTech#a80885", "/9punkt/2021-01-07.html?highlight=BioNTech#a80885", "/9punkt/2021-01-07.html?highlight=BioNTech#a80885", "/9punkt/2020-11-16.html?highlight=BioNTech#a80174", "/9punkt/2020-11-16.html?highlight=BioNTech#a80174", "/9punkt/2020-11-16.html?highlight=BioNTech#a80174", "/stichwort/bio-ntech/presseschauen.html?p=1&q=", "/stichwort/bio-ntech/presseschauen.html?keyword_rubrik=9punkt&q=", "/stichwort/bio-ntech/presseschauen.html?keyword_rubrik=magazinrundschau&q=", "/werbung-mediadaten/werben-beim-perlentaucher.html", "/werbung-mediadaten/werben-beim-perlentaucher.html", "/", "/teaserliste/1_Presseschauen.html", "/teaserliste/2_Buecher.html", "/autoren/", "/stichwort/", "/teaserliste/6_Kolumnen.html", "/teaserliste/3_Magazin.html", "/teaserliste/9_Debatte.html", "/teaserliste/10_kino_tv.html", "/teaserliste/11_Post-aus.html", "/werbung-mediadaten/werben-beim-perlentaucher.html", "/teaserliste/4_Service.html", "/teaserliste/12_Ueber-Uns.html", "/newsletter", "/impressum-kontakt/impressum-kontakt.html", "/impressum-kontakt/datenschutzerklaerung-der-perlentaucher-medien-gmb-h.html", "https://eichendorff21.de"]}